NCT04294953 is a Phase 2 clinical trial of Duloxetine in Colorectal Cancer, sponsored by Assiut University.

Who is sponsoring NCT04294953?

NCT04294953 is sponsored by Assiut University.

What drugs are being tested in NCT04294953?

Interventions in NCT04294953: Duloxetine, Placebo oral tablet.

What condition does NCT04294953 study?

NCT04294953 studies Colorectal Cancer.

Is NCT04294953 still recruiting?

NCT04294953 is currently status unknown. Last updated 4 March 2020.

Last reviewed 2020-03-04 · How we verify

NCT04294953

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Perioperative Duloxetine as a Part of Multimodal Analgesia in Laparoscopic Colorectal Cancer Surgery

Status unknown Phase 2 Last updated 4 March 2020

What this trial tests

Phase 2 trial testing Duloxetine in Colorectal Cancer in 60 participants. Status unknown.

Timeline

1 March 2020

Primary endpoint
1 March 2021

1 April 2021

Quick facts

Lead sponsor	Assiut University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	60
Start date	1 March 2020
Primary completion	1 March 2021
Estimated completion	1 April 2021

Drugs / interventions tested

Duloxetine (duloxetine) — full drug profile →
Placebo oral tablet — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Assiut University

Who can join

Adults 18 to 65, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our aim will be to evaluate the efficacy of perioperative Duloxetine in decreasing acute postoperative pain after laparoscopic colorectal cancer surgery and its role in reducing postoperative morphine requirements

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach.
Fadaka AO, Akinsoji T, Klein A, Madiehe AM, et al · · 2023 · cited 17× · PMID 38174117 · DOI 10.1016/j.jpha.2023.07.008
Efficacy of perioperative duloxetine as a part of multimodal analgesia in laparoscopic colorectal cancer surgeries.
Fuad Hetta D, Abdelfatah Mohamed M, Elmorabaa HA, Ahmed MI, et al · · 2023 · PMID 37194004 · DOI 10.1186/s12871-023-02119-8

Verify or expand the search:

Other trials of Duloxetine

Trials testing the same drug.

NCT07431606 — Duloxetine in Inflammatory Bowel Diseases · Phase 2 · not yet recruiting
NCT07326163 — The Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients · NA · enrolling by invitation
NCT06860984 — Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatograph · Phase 3 · recruiting
NCT06807866 — Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT · Phase 4 · recruiting
NCT06711978 — Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a R · NA · not yet recruiting

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04294953 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 4 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04294953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing